Publicacions en col·laboració amb investigadors/es de Medical University of Graz (19)

2024

  1. Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022

    eClinicalMedicine, Vol. 71

2022

  1. Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients—a multinational observational study by the European Confederation of Medical Mycology

    Clinical Microbiology and Infection, Vol. 28, Núm. 4, pp. 580-587

2021

  1. Genomic and transcriptomic analyses of breast cancer primaries and matched metastases in Aurora, the breast international group (Big) molecular screening initiative

    Cancer Discovery, Vol. 11, Núm. 11, pp. 2796-2811

  2. Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509)

    Journal of Clinical Oncology, Vol. 39, Núm. 20, pp. 2304-2312

  3. Management of anaphylaxis due to COVID-19 vaccines in the elderly

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 10, pp. 2952-2964

  4. PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis

    Journal of Hepatology, Vol. 74, Núm. 5, pp. 1097-1108

  5. Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification—an approach to classification of patients with t-MDS

    Leukemia, Vol. 35, Núm. 3, pp. 835-849

2020

  1. Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF

    Journal of Hepatology, Vol. 72, Núm. 4, pp. 688-701

  2. Correction to ‘Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF’ [J Hepatol 2020 (72) 688–701] (Journal of Hepatology (2020) 72(4) (688–701), (S0168827819306968), (10.1016/j.jhep.2019.11.009))

    Journal of Hepatology

  3. Efficacy of Albumin Treatment for Patients with Cirrhosis and Infections Unrelated to Spontaneous Bacterial Peritonitis

    Clinical Gastroenterology and Hepatology, Vol. 18, Núm. 4, pp. 963-973.e14

  4. The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology

    Journal of Hepatology, Vol. 73, Núm. 4, pp. 842-854

2019

  1. Orchestration of Tryptophan-Kynurenine Pathway, Acute Decompensation, and Acute-on-Chronic Liver Failure in Cirrhosis

    Hepatology, Vol. 69, Núm. 4, pp. 1686-1701

2018

  1. Allergen manufacturing and quality aspects for allergen immunotherapy in Europe and the United States: An analysis from the EAACI AIT Guidelines Project

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 73, Núm. 4, pp. 816-826

  2. Challenges in the implementation of EAACI guidelines on allergen immunotherapy: A global perspective on the regulation of allergen products

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 73, Núm. 1, pp. 64-76

2015

  1. Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice

    Clinical Rheumatology, Vol. 34, Núm. 3, pp. 563-571

  2. Erratum to: Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice [Clin Rheumatol, (2015), (34), 563-571, DOI 10.1007/s10067-014-2857-y]

    Clinical Rheumatology

  3. Proceedings of the EUGMS Full Board workshop, Vienna, March 4th 2015

    European Geriatric Medicine

2013

  1. Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: Results of a phase II trial

    European Journal of Cancer, Vol. 49, Núm. 2, pp. 386-394

2011

  1. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: A consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer

    Journal of Clinical Oncology, Vol. 29, Núm. 18, pp. 2598-2607